| Jun 21 |
Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug
|
| Jun 21 |
5 Things to Know Before the Stock Market Opens
|
| Jun 21 |
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy
|
| Jun 21 |
Sarepta Stock Jumps on Expanded FDA Approval for Duchenne Muscular Dystrophy Gene Therapy
|
| Jun 21 |
These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, Gilead, CarMax, and More
|
| Jun 21 |
Biggest stock movers: ASAN, SWBI, and more
|
| Jun 21 |
Update: Sarepta Therapeutics Gets Expanded Label FDA Approval for Duchenne Muscular Dystrophy; Shares Soar Premarket
|
| Jun 20 |
Sarepta Jumps on Broad Approval for Muscular Dystrophy Drug
|
| Jun 20 |
Sarepta surges 38% after hours on expanded Elevidys Duchenne approval (updated)
|
| Jun 20 |
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
|
